ARTICLE | Product Development
TIGIT frenzy doesn’t end with Roche’s Phase III miss
Tiragolumab miss is a major blow, but differentiated blockers against the target fill the pipeline
May 11, 2022 6:42 PM UTC
The failure of Roche’s tiragolumab in a Phase III trial deals a blow to expectations for TIGIT inhibition, but isn’t yet a death knell for a pipeline of differentiated programs aiming at the checkpoint target.
Roche (SIX:ROG; OTCQX:RHHBY) said Wednesday that data from the SKYSCRAPER-01 trial showed tiragolumab plus Tecentriq atezolizumab did not significantly extend progression-free survival (PFS) compared with Tecentriq alone as first-line therapy in patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC)...
BCIQ Company Profiles
BCIQ Target Profiles